293 related articles for article (PubMed ID: 12665117)
1. Buprenorphine: new pharmacological aspects.
Cowan A
Int J Clin Pract Suppl; 2003 Feb; (133):3-8; discussion 23-4. PubMed ID: 12665117
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine: considerations for pain management.
Johnson RE; Fudala PJ; Payne R
J Pain Symptom Manage; 2005 Mar; 29(3):297-326. PubMed ID: 15781180
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
6. Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine.
Yu G; Yue YJ; Cui MX; Gong ZH
J Pharmacol Exp Ther; 2006 Jul; 318(1):282-7. PubMed ID: 16569757
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine-induced hyperalgesia in the rat.
Wala EP; Holtman JR
Eur J Pharmacol; 2011 Jan; 651(1-3):89-95. PubMed ID: 21114985
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of opioid receptor occupancy of buprenorphine in vivo.
Englberger W; Kögel B; Friderichs E; Strassburger W; Germann T
Eur J Pharmacol; 2006 Mar; 534(1-3):95-102. PubMed ID: 16490191
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine: a primer for emergency physicians.
Sporer KA
Ann Emerg Med; 2004 May; 43(5):580-4. PubMed ID: 15111917
[TBL] [Abstract][Full Text] [Related]
11. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation.
Mégarbane B; Marie N; Pirnay S; Borron SW; Gueye PN; Risède P; Monier C; Noble F; Baud FJ
Toxicol Appl Pharmacol; 2006 May; 212(3):256-67. PubMed ID: 16169027
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.
Ohtani M; Kotaki H; Sawada Y; Iga T
J Pharmacol Exp Ther; 1995 Feb; 272(2):505-10. PubMed ID: 7853163
[TBL] [Abstract][Full Text] [Related]
14. Current knowledge of buprenorphine and its unique pharmacological profile.
Pergolizzi J; Aloisi AM; Dahan A; Filitz J; Langford R; Likar R; Mercadante S; Morlion B; Raffa RB; Sabatowski R; Sacerdote P; Torres LM; Weinbroum AA
Pain Pract; 2010; 10(5):428-50. PubMed ID: 20492579
[TBL] [Abstract][Full Text] [Related]
15. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
16. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence.
Codd EE; Carson JR; Colburn RW; Stone DJ; Van Besien CR; Zhang SP; Wade PR; Gallantine EL; Meert TF; Molino L; Pullan S; Razler CM; Dax SL; Flores CM
J Pharmacol Exp Ther; 2009 Apr; 329(1):241-51. PubMed ID: 19151246
[TBL] [Abstract][Full Text] [Related]
17. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
[TBL] [Abstract][Full Text] [Related]
18. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
Kress HG
Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516
[TBL] [Abstract][Full Text] [Related]
19. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.
Gallantine EL; Meert TF
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):419-27. PubMed ID: 18699797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]